Intention notice: Reagents for genotyping dihydropyrimidin dehydrogenase (DPYD) and reagents/kits for gene analyses for Helse Bergen HF

Description du marché

Bergen Regional Health Authority currently has framework agreements with triolab for the purchase of reagents for genotyping dihydropyrimidin dehydrogenase (DPYD) and reagents/kits for gene analyses. This material is used by the Cancer Genetics Department at Haukeland University Hospital. Current agreements expire and Helse Bergen therefore needs new contracts that come into force when current agreements expire. The company merges the current contracts into one contract when a new framework agreement is signed. The reagents must be compatible with the LC480 II instrument procured in 2021. Necessary reagents that are compatible with the existing equipment and method can only be procured by Triolab AS, and on this basis a competition cannot be arranged, cf. the Public Procurement Regulations § 13-4 letters b (2 and 3). An agreement is planned to be signed 10 days at the earliest after publication of an intention notice. The contract will start at the earliest in week 33 2025 due to staff holidays.

Pouvoir adjudicateur